770.05 -4.92 (-0.64%) Buy

Don't consider investing in AUROPHARMA now, it is risky at the moment

13 min read

AUROBINDO PHARMA LTD delivered lacklustre performance today. It returned -0.64% to close at 770.05. It's recent 5 day performance has been -1.69%, +0.22%, +2.12%, +0.05% and -0.91%.

[Themes containing AUROPHARMA]

AUROPHARMA showed a up trend over the last 3 months. During this period AUROPHARMA returned +2.97% and saw a maximum drawdown of -13.56%. It has been unusually choppy during this period. Long term investors are better off avoiding investing in AUROPHARMA till volatility reduces and a clear trend emerges.


AUROPHARMA has been outperforming the NIFTY-50 index in recent time. Over the last 3 years and 1 month, AUROPHARMA underperformed the NIFTY-50 index on 53% days.

During the last three months AUROPHARMA delivered losses on 51% days. However, it still managed to end this period in a profit. It's best return during this period (of +7.41%) was on Monday, 29 Oct, 2018. While it's worst loss in the same period (of -5.53%) was on Thursday, 6 Dec, 2018. There was initially a bullish trend during this period which started on 6 Nov, 2018 and went on till 9 Nov, 2018. The bullish trend returned +4.59% to investors. This was followed by a bearish trend that started on 18 Dec, 2018 and ended on 24 Dec, 2018. This bearish trend lost -4.11% of investor capital.

On monthly basis, AUROPHARMA delivered profits in more months over the last year, than losses. AUROPHARMA delivered profits in more months than NIFTY-50 index. AUROPHARMA significantly outperformed NIFTY-50 index in Aug 2018, when it returned +20.53% compared to +6.56% returned by NIFTY-50 index during it's best month in the last one year - Jul 2018. AUROPHARMA had a longer winning streak of profitable months than NIFTY-50 index. It went up in 4 straight months (from Aug 2018 to Nov 2018) during which period it delivered +30.42%. It is interesting to note that both AUROPHARMA and NIFTY-50 index significantly outperform during months when quarterly/annual results are announced.

The individual investor should act consistently as an investor and not as a speculator.
-- Ben Graham

AUROPHARMA is becoming less volatile overall. In comparison, the NIFTY-50 index is seeing a fall in volatility. During the last three months, there was a significant fall in AUROPHARMA's volatility from 29 Oct, 2018 to 3 Jan, 2019. While there was a significant fall in the NIFTY-50 index's volatility from 31 Oct, 2018 to 5 Dec, 2018.

Advanced/professional short-term investors should note that AUROPHARMA has negative skewness in it's return distribution. This indicates that investors may need to stay invested through long periods of drawdown before expecting a recovery.

Investors trading in AUROPHARMA derivatives at this moment can consider 'Long Strangle' options strategy to receive better risk-adjusted returns.

AUROPHARMA has more chance of extreme outcomes than the NIFTY-50 index. Therefore, AUROPHARMA must receive a lower allocation than NIFTY-50 in your portfolio. NIFTY-50 index usually has shorter drawdown period than AUROPHARMA.

On a general note (since you are interested in AUROPHARMA), two instruments that deserve special mention are LTTS and CUB. They have significantly outperformed the overall market this year.

Want to improve your Portfolio's performance?

Spotalpha's Portfolio optimizer is all you need to improve your returns and reduce your risk.
Optimize Portfolio NOW
If you liked what you read here ...

... we have a small favour to ask. Help us bring the power of algorithmic trading strategies to individual investors.

All content in this article was automatically generated by algorithms. This ensures that there are no human biases in the analysis provided. This approach to investing is not new and has been around for more than three decades. Yet, it has been available to only the most affluent or elite investors leaving individual investors to trade on emotions (such as fear and greed), intuition and poor analysis from third-parties. We want to change this.

We want to empower investors with all the tools and analysis required by them to make a rational investment decision.

If you found Spotalpha useful, consider making a contribution. For as little as $5 you can support our efforts and it takes less than a minute. Thank you. Contribute
Share with friends   WhatsApp   Facebook   Twitter